There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Collegium Pharmaceutical (COLL – Research Report), Moderna (MRNA – Research Report) and AlloVir (ALVR – Research Report) with bullish sentiments.
Collegium Pharmaceutical (COLL)
In a report released today, David Amsellem from Piper Sandler reiterated a Buy rating on Collegium Pharmaceutical, with a price target of $35.00. The company’s shares closed last Thursday at $22.20.
According to TipRanks.com, Amsellem has 0 stars on 0-5 stars ranking scale with an average return of
Currently, the analyst consensus on Collegium Pharmaceutical is a Strong Buy with an average price target of $33.33, a 51.2% upside from current levels. In a report issued on May 2, Jefferies also assigned a Buy rating to the stock with a $30.00 price target.
See the top stocks recommended by analysts >>
Moderna (MRNA)
In a report released today, Edward Tenthoff from Piper Sandler reiterated a Buy rating on Moderna, with a price target of $214.00. The company’s shares closed last Thursday at $134.33.
According to TipRanks.com, Tenthoff is a 5-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Moderna with a $221.92 average price target, representing a 65.7% upside. In a report issued on April 30, Jefferies also maintained a Buy rating on the stock with a $275.00 price target.
AlloVir (ALVR)
Piper Sandler analyst Christopher Raymond maintained a Buy rating on AlloVir today and set a price target of $30.00. The company’s shares closed last Thursday at $4.26, close to its 52-week low of $3.17.
According to TipRanks.com, Raymond is a 4-star analyst with an average return of
AlloVir has an analyst consensus of Strong Buy, with a price target consensus of $22.00, which is a 465.6% upside from current levels. In a report issued on April 26, Morgan Stanley also maintained a Buy rating on the stock with a $20.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on COLL:
- Collegium Reports First Quarter 2023 Financial Results
- Collegium Pharmaceutical assumed with a Buy at Jefferies
- COLL Earnings this Week: How Will it Perform?
- Collegium Pharmaceutical price target lowered to $35 from $37 at Piper Sandler
- Collegium to Report First Quarter 2023 Financial Results on May 4, 2023
